<DOC>
	<DOCNO>NCT00003268</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . Chemoprotective drug , amifostine , may protect normal cell side effect chemotherapy . PURPOSE : Phase I trial study effectiveness amifostine treat patient newly diagnose acute myeloid leukemia receive idarubicin plus cytarabine .</brief_summary>
	<brief_title>Amifostine Combination Chemotherapy Treating Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether amifostine provide systemic protection nonhematologic side effect idarubicin ( IDR ) induction therapy acute myeloid leukemia ( AML ) , allow dose idarubicin escalate . - Determine maximum tolerate dose idarubicin amifostine use chemotherapy protectant . - Determine incidence severity dose limit hypotension patient receive amifostine ability offset side effect vasoconstrictive agent . - Determine whether additional side effect amifostine dose limit patient AML treat IDR cytarabine ( ARA-C ) . - Monitor frequency alopecia , mucositis , diarrhea , septicemia involve enteric pathogen patient . - Determine requirement intravenous hyperalimentation patient receive amifostine , IDR , ARA-C. OUTLINE : This dose escalation study idarubicin ( IDR ) . Patients receive amifostine IV 15 minute , follow 15-30 minute later chemotherapy . Idarubicin IV administer 15 minute day 1-3 . Cytarabine administer continuous infusion day 1-7 . Patients may receive 1 additional course treatment , necessary . Cohorts 3-6 patient treat dose level idarubicin . Dose escalation discontinue 2 patient experience dose limit toxicity . Patients follow 3 month . PROJECTED ACCRUAL : A maximum 36 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose acute myeloid leukemia ( AML ) M0M2 , M4M7 Histologically proven bone marrow aspirate biopsy ( requirement may waive patient overt leukemia peripheral blood ) M3 ( acute promyelocytic leukemia ) patient exclude unless already treat trans retinoic acid Evaluable disease PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % ECOG 02 Life expectancy : At least 3 month Hematopoietic : Not specify Hepatic : SGOT/SGPT great 2.5 time upper limit normal Renal : Creatinine great 2.0 mg/dL Cardiovascular : Ejection fraction least 50 % Must able stop take antihypertensive medication 24 hour prior cytarabine administration Other : No preexist severe organ dysfunction No history underlie medical psychiatric illness may impair patient 's ability participate study Not pregnant nursing Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No prior cytotoxic therapy AML No prior amifostine At least 1 month since chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 1 month since radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2003</verification_date>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute monoblastic leukemia acute monocytic leukemia ( M5 )</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>drug/agent toxicity tissue/organ</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
</DOC>